CN105708803A - 叶酸靶向水飞蓟素固体脂质纳米粒制备方法 - Google Patents

叶酸靶向水飞蓟素固体脂质纳米粒制备方法 Download PDF

Info

Publication number
CN105708803A
CN105708803A CN201410725936.0A CN201410725936A CN105708803A CN 105708803 A CN105708803 A CN 105708803A CN 201410725936 A CN201410725936 A CN 201410725936A CN 105708803 A CN105708803 A CN 105708803A
Authority
CN
China
Prior art keywords
folic acid
peg3350
solid lipid
silymarin
cephalin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201410725936.0A
Other languages
English (en)
Inventor
于莲
田丽华
赵岩
杨春荣
苏瑾
孙维彤
杜研
周彤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiamusi University
Original Assignee
Jiamusi University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiamusi University filed Critical Jiamusi University
Priority to CN201410725936.0A priority Critical patent/CN105708803A/zh
Publication of CN105708803A publication Critical patent/CN105708803A/zh
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本发明涉及一种叶酸靶向水飞蓟素固体脂质纳米粒制备方法,它是首先将叶酸-聚乙二醇3350-脑磷脂进行合成,再将叶酸修饰的水飞蓟素固体脂质体纳米粒进行制备。该发明将水飞蓟素制成固体脂质纳米粒并连接靶头叶酸,纳米粒静脉注射后具有靶向肺部的作用,叶酸修饰可使药物靶向肿瘤细胞,因此产生肺部肿瘤靶向作用,提高抗肿瘤药物的生物利用度,减少细胞毒副作用,治疗效果好,使患者能够减少痛苦,早日康复,本发明制备方法简便,对环境无污染,成本低,有利于推广应用。

Description

叶酸靶向水飞蓟素固体脂质纳米粒制备方法
技术领域
本发明是以叶酸为靶头制备叶酸靶向水飞蓟素固体脂质纳米粒。
背景技术
目前,肺癌已成为全世界死亡率最高的癌症,治疗肺癌的药物虽然较多,但都不能靶向给药,现国内无水飞蓟素叶酸靶向制剂,使药物直达病灶,在治疗时毒副作用大,即杀死了癌细胞,也杀死了正常细胞,患者治疗痛苦,体力下降,免疫功能低下,治疗效果差,患者所花医疗费用高,而且癌症不能达到治愈。
发明内容
本发明的目的在于克服上述缺点,提供一种叶酸靶向水飞蓟素固体脂质纳米粒制备方法,它是以叶酸为靶头,将水飞蓟素制成固体脂质纳米粒并连接靶头,采用静脉注射途径给药,使该制剂具有肺肿瘤的靶向性,本发明的目的是这样实现的,
将水飞蓟素制成固体脂质纳米粒并连接靶头叶酸,制成叶酸靶向的水飞蓟宾固体脂质纳米粒,
第一步、FA-PEG3350-DSPE(叶酸-聚乙二醇3350-脑磷脂)的合成
合成步骤如下:①分别称取65.8mgFA(叶酸)、350mgH2N-PEG3350-NH2(二氨基-聚乙二醇3350)、30mgNHS(羟基琥珀酸酰亚胺)、60mgDCC(N,N′-二环己基碳二亚胺)溶解于1mLDMSO(二甲基亚砜)中,依次加入,加入100μLTEA(三乙胺),N2(氮气)保护、避光反应24h后50℃(500r·min-1)反应6h,加入45mL冷氯仿混匀,旋转蒸发去除氯仿,残留少许液体,真空干燥得淡黄色固体FA-PEG3350-NH2(氨基-叶酸-聚乙二醇3350),②50mgDSPE(脑磷脂)溶于2.5mLCHCl3(三氯甲烷),15mgSUC(琥珀酸酐)溶于0.5mlDMSO(二甲基亚砜),转入前一体系①中,逐渐加入50μLTEA(三乙胺),500r·min-1室温反应24h,残留少许液体,加入45mL无水冷丙酮沉淀,离心(12000r·min-1,10min),反复清洗沉淀3次,真空干燥得SUC-DSPE(琥珀酸脑磷脂),③将SUC-DSPE(琥珀酸脑磷脂)溶解在10mLCHCl3(三氯甲烷)中后转入前一体系②中,加入30mgDCC(N,N′-二环己基碳二亚胺)室温反应4h活化羧基,称取200mgFA-PEG3350-NH2(氨基-叶酸-聚乙二醇3350)溶解在10mL的CHCl3(三氯甲烷)中,加入40μLTEA,室温反应24h,冷丙酮沉淀并清洗产物,得产物FA-PEG3350-DSPE(叶酸-聚乙二醇3350-脑磷脂);
第二步、叶酸修饰的水飞蓟素固体脂质体纳米粒制备
2.0%单硬脂酸甘油酯加入少量无水乙醇助融,10mg水飞蓟宾,水浴加热70℃熔融,作为油相,油相中加入3%膜材(溶于氯仿),称取2.4%泊洛沙姆188,加入20mL蒸馏水超声溶解,称取0.8%脑磷脂,加入少量无水乙醇超声溶解后加入泊洛沙姆188中,作为水相,将水相加热至同温度后以10ml·min-1的速度滴加至油相中,乳化10min后超声破碎(600w,8min,3s间隔),置于4℃水浴中固化,0.22μm滤膜过滤即得叶酸修饰水飞蓟宾固体脂质纳米粒(FA-SIL-SLN)。本发明将水飞蓟素制成固体脂质纳米粒并连接靶头叶酸,纳米粒静脉注射后具有靶向肺部的作用,叶酸修饰可使药物靶向肿瘤细胞,因此产生肺部肿瘤靶向作用,提高抗肿瘤药物的生物利用度,减少细胞毒副作用,治疗效果好,使患者能够减少痛苦,早日康复。固体脂质纳米粒,是一种以室温下为固态的天然或合成的脂质或类脂为基质,将药物包裹于类脂核中制成粒径约为50-1000nm的固体脂质粒子给药体系,是一种很有发展前景的新型载药系统。随着对肿瘤分子水平研究的不断深入,在肿瘤细胞表面发现了一系列受体,它们与肿瘤生长增殖密切相关并在肿瘤组织过度表达,它们与特异性抗体或配体结合可诱导细胞内化,这种肿瘤特异性的受体为肿瘤治疗提供了靶点,使传统的化疗药物和新发现的肿瘤特异性的配体或抗体结合,增强了药物的肿瘤选择性并减少药物的毒副作用,叶酸受体(folatereceptor,FR)是一种可以介导细胞内化,将叶酸摄取入真核细胞胞浆的一种高亲和力受体,在正常组织中极少表达,而在上皮组织来源的恶性肿瘤如肺癌、卵巢癌、宫颈癌、乳腺癌、结肠癌等组织中高度表达。本发明是以叶酸为靶头,将水飞蓟素制成固体脂质纳米粒并连接靶头,采用静脉注射途径给药,使该制剂具有肺肿瘤的靶向性,对水飞蓟素治疗药物研究与开发具有积极的意义,本发明制备方法简便,对环境无污染,成本低,有利于推广应用。
下面是本发明的具体实施例:
将水飞蓟素制成固体脂质纳米粒并连接靶头叶酸,制成叶酸靶向的水飞蓟宾固体脂质纳米粒,
第一步、FA-PEG3350-DSPE(叶酸-聚乙二醇3350-脑磷脂)的合成
合成步骤如下:①分别称取65.8mgFA(叶酸)、350mgH2N-PEG3350-NH2(二氨基-聚乙二醇3350)、30mgNHS(羟基琥珀酸酰亚胺)、60mgDCC(N,N′-二环己基碳二亚胺)溶解于1mLDMSO(二甲基亚砜)中,依次加入,加入100μLTEA(三乙胺),N2(氮气)保护、避光反应24h后50℃(500r·min-1)反应6h,加入45mL冷氯仿混匀,旋转蒸发去除氯仿,残留少许液体,真空干燥得淡黄色固体FA-PEG3350-NH2(氨基-叶酸-聚乙二醇3350),②50mgDSPE(脑磷脂)溶于2.5mLCHCl3(三氯甲烷),15mgSUC(琥珀酸酐)溶于0.5mlDMSO(二甲基亚砜),转入前一体系①中,逐渐加入50μLTEA(三乙胺),500r·min-1室温反应24h,残留少许液体,加入45mL无水冷丙酮沉淀,离心(12000r·min-1,10min),反复清洗沉淀3次,真空干燥得SUC-DSPE(琥珀酸脑磷脂),③将SUC-DSPE(琥珀酸脑磷脂)溶解在10mLCHCl3(三氯甲烷)中,加入30mgDCC(N,N′-二环己基碳二亚胺)室温反应4h活化羧基,称取200mgFA-PEG3350-NH2(氨基-叶酸-聚乙二醇3350)溶解在10mL的CHCl3(三氯甲烷)中后转入前一体系②中,加入40μLTEA,室温反应24h,冷丙酮沉淀并清洗产物,得产物FA-PEG3350-DSPE(叶酸-聚乙二醇3350-脑磷脂);
第二步、叶酸修饰的水飞蓟素固体脂质体纳米粒制备
2.0%单硬脂酸甘油酯加入少量无水乙醇助融,10mg水飞蓟宾,水浴加热70℃熔融,作为油相,油相中加入3%膜材(溶于氯仿),称取2.4%泊洛沙姆188,加入20mL蒸馏水超声溶解,称取0.8%脑磷脂,加入少量无水乙醇超声溶解后加入泊洛沙姆188中,作为水相,将水相加热至同温度后以10ml·min-1的速度滴加至油相中,乳化10min后超声破碎(600w,8min,3s间隔),置于4℃水浴中固化,0.22μm滤膜过滤即得叶酸修饰水飞蓟宾固体脂质纳米粒(FA-SIL-SLN)。
本药所含成分分析及配伍禁忌:
本制剂以水飞蓟素为指标成分,采用HPLC方法检测。水飞蓟素为中药水飞蓟种子提取的黄酮类物质,无配伍禁忌。

Claims (1)

1.一种叶酸靶向水飞蓟素固体脂质纳米粒制备方法,其特征在于:将水飞蓟素制成固体脂质纳米粒并连接靶头叶酸,制成叶酸靶向的水飞蓟宾固体脂质纳米粒,
第一步、FA-PEG3350-DSPE(叶酸-聚乙二醇3350-脑磷脂)的合成
合成步骤如下:①分别称取65.8mgFA(叶酸)、350mgH2N-PEG3350-NH2(二氨基-聚乙二醇3350)、30mgNHS(羟基琥珀酸酰亚胺)、60mgDCC(N,N′-二环己基碳二亚胺)溶解于1mLDMSO(二甲基亚砜)中,依次加入,加入100μLTEA(三乙胺),N2(氮气)保护、避光反应24h后50℃(500r·min-1)反应6h,加入45mL冷氯仿混匀,旋转蒸发去除氯仿,残留少许液体,真空干燥得淡黄色固体FA-PEG3350-NH2(氨基-叶酸-聚乙二醇3350),②50mgDSPE(脑磷脂)溶于2.5mLCHCl3(三氯甲烷),15mgSUC(琥珀酸酐)溶于0.5mlDMSO(二甲基亚砜),转入前一体系①中,逐渐加入50μLTEA(三乙胺),500r·min-1室温反应24h,残留少许液体,加入45mL无水冷丙酮沉淀,离心(12000r·min-1,10min),反复清洗沉淀3次,真空干燥得SUC-DSPE(琥珀酸脑磷脂),③将SUC-DSPE(琥珀酸脑磷脂)溶解在10mLCHCl3(三氯甲烷)中,加入30mgDCC(N,N′-二环己基碳二亚胺)室温反应4h活化羧基,称取200mgFA-PEG3350-NH2(氨基-叶酸-聚乙二醇3350)溶解在10mL的CHCl3(三氯甲烷)中后转入前一体系②中,加入40μLTEA,室温反应24h,冷丙酮沉淀并清洗产物,得产物FA-PEG3350-DSPE(叶酸-聚乙二醇3350-脑磷脂);
第二步、叶酸修饰的水飞蓟素固体脂质体纳米粒制备
2.0%单硬脂酸甘油酯加入少量无水乙醇助融,10mg水飞蓟宾,水浴加热70℃熔融,作为油相,油相中加入3%膜材(溶于氯仿),称取2.4%泊洛沙姆188,加入20mL蒸馏水超声溶解,称取0.8%脑磷脂,加入少量无水乙醇超声溶解后加入泊洛沙姆188中,作为水相,将水相加热至同温度后以10ml·min-1的速度滴加至油相中,乳化10min后超声破碎(600w,8min,3s间隔),置于4℃水浴中固化,0.22μm滤膜过滤即得叶酸修饰水飞蓟宾固体脂质纳米粒(FA-SIL-SLN)。
CN201410725936.0A 2014-12-04 2014-12-04 叶酸靶向水飞蓟素固体脂质纳米粒制备方法 Pending CN105708803A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410725936.0A CN105708803A (zh) 2014-12-04 2014-12-04 叶酸靶向水飞蓟素固体脂质纳米粒制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410725936.0A CN105708803A (zh) 2014-12-04 2014-12-04 叶酸靶向水飞蓟素固体脂质纳米粒制备方法

Publications (1)

Publication Number Publication Date
CN105708803A true CN105708803A (zh) 2016-06-29

Family

ID=56142916

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410725936.0A Pending CN105708803A (zh) 2014-12-04 2014-12-04 叶酸靶向水飞蓟素固体脂质纳米粒制备方法

Country Status (1)

Country Link
CN (1) CN105708803A (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107137377A (zh) * 2017-03-29 2017-09-08 浙江大学 一种肿瘤干细胞靶向脂质纳米粒及制备方法与应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
于莲等: "叶酸修饰水飞蓟宾固体脂质纳米粒的制备及其对A459细胞抑制作用研究", 《中草药》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107137377A (zh) * 2017-03-29 2017-09-08 浙江大学 一种肿瘤干细胞靶向脂质纳米粒及制备方法与应用
CN107137377B (zh) * 2017-03-29 2019-10-11 浙江大学 一种肿瘤干细胞靶向脂质纳米粒及制备方法与应用

Similar Documents

Publication Publication Date Title
Soe et al. Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy
Lee et al. Mitochondria targeting and destabilizing hyaluronic acid derivative-based nanoparticles for the delivery of lapatinib to triple-negative breast cancer
Chandran et al. Nano drug delivery strategy of 5-fluorouracil for the treatment of colorectal cancer
Zhao et al. Nanotechnology for cancer therapy based on chemotherapy
Ghanbari-Movahed et al. Recent advances in improved anticancer efficacies of camptothecin nano-formulations: A systematic review
Zhang et al. Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells
Radhakrishnan et al. Bombesin conjugated solid lipid nanoparticles for improved delivery of epigallocatechin gallate for breast cancer treatment
Liu et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelles
Zhu et al. Smart nanoplatform for sequential drug release and enhanced chemo-thermal effect of dual drug loaded gold nanorod vesicles for cancer therapy
Tian et al. A wogonin-loaded glycyrrhetinic acid-modified liposome for hepatic targeting with anti-tumor effects
Thakur et al. Self-assembled gold nanoparticle–lipid nanocomposites for on-demand delivery, tumor accumulation, and combined photothermal–photodynamic therapy
Zhao et al. Construction of homologous cancer cell membrane camouflage in a nano-drug delivery system for the treatment of lymphoma
Hou et al. Multifunctional hyaluronic acid modified graphene oxide loaded with mitoxantrone for overcoming drug resistance in cancer
Wu et al. pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma
CN101791411A (zh) 两亲性多糖偶联物及其药物组合物的制备和应用
Lv et al. Intracellularly degradable, self-assembled amphiphilic block copolycurcumin nanoparticles for efficient in vivo cancer chemotherapy
CN104398493A (zh) 一种可逆转肿瘤耐药的肿瘤主动靶向纳米递药系统
Zhao et al. Green synthesis of gold nanoparticles from Dendrobium officinale and its anticancer effect on liver cancer
Ding et al. Salvianolic acid B protects against myocardial damage caused by nanocarrier TiO2; and synergistic anti-breast carcinoma effect with curcumin via codelivery system of folic acid-targeted and polyethylene glycol-modified TiO2 nanoparticles
Dong et al. “Attractive/adhesion force” dual-regulatory nanogels capable of CXCR4 antagonism and autophagy inhibition for the treatment of metastatic breast cancer
CN102379848A (zh) 一种紫杉醇免疫纳米脂质体及其制备方法和用途
Wang et al. Folic Acid–Conjugated Pyropheophorbide a as the Photosensitizer Tested for In Vivo Targeted Photodynamic Therapy
Fu et al. Polymeric Nanosystems for Immunogenic Cell Death‐Based Cancer Immunotherapy
CN105566271B (zh) 双黄酮化合物及其制备治疗癌症的药物的用途
CN106750272B (zh) 一种水溶性蛇葡萄素聚合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160629

WD01 Invention patent application deemed withdrawn after publication